Insider Trades86 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 20,000 | $178.41 | $609.1B | -6.08% | +55.91% | $3.6M | +0.00% | — | Stalk |
| May 1, 2026 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 11,002 | $229.85 | $609.1B | -6.08% | +55.91% | $2.5M | -30.64% | — | Stalk |
| Feb 27, 2026 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 8,150 | $181.77 | $609.1B | -6.08% | +55.91% | $1.5M | +0.00% | — | Stalk |
| Feb 20, 2026 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 1,322 | $245.66 | $609.1B | -6.08% | +55.91% | $324.8K | -4.94% | — | Stalk |
| Feb 15, 2026 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 106,492 | $201.24 | $609.1B | -6.08% | +55.91% | $21.4M | -1.14% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 1,055 | $244.35 | $609.1B | -6.08% | +55.91% | $257.8K | -1.06% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Kristen Mulholland | EVP, Chief HR Officer | 1,585 | $244.26 | $609.1B | -6.08% | +55.91% | $387.1K | -1.58% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 7,266 | $244.45 | $609.1B | -6.08% | +55.91% | $1.8M | -1.53% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Elizabeth Forminard | EVP, Chief Legal Officer | 8,361 | $244.41 | $609.1B | -6.08% | +55.91% | $2.0M | -6.66% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 10,611 | $243.82 | $609.1B | -6.08% | +55.91% | $2.6M | -6.58% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 15,717 | $244.43 | $609.1B | -6.08% | +55.91% | $3.8M | -1.87% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 47,533 | $185.72 | $609.1B | -6.08% | +55.91% | $8.8M | -0.84% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 36,230 | $244.44 | $609.1B | -6.08% | +55.91% | $8.9M | -2.53% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | James D. Swanson | EVP, CIO | 128,373 | $205.20 | $609.1B | -6.08% | +55.91% | $26.3M | -1.26% | — | Stalk |
| Feb 13, 2026 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 172,477 | $199.41 | $609.1B | -6.08% | +55.91% | $34.4M | -7.17% | — | Stalk |
| Feb 6, 2026 | Buy | JNJ | Kristen Mulholland | EVP, Chief HR Officer | 8,960 | $153.28 | $609.1B | -6.08% | +55.91% | $1.4M | +6.76% | — | Stalk |
| Feb 6, 2026 | Buy | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 25,906 | $156.97 | $609.1B | -6.08% | +55.91% | $4.1M | +10.61% | — | Stalk |
| Feb 6, 2026 | Buy | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 66,215 | $158.75 | $609.1B | -6.08% | +55.91% | $10.5M | +5.13% | — | Stalk |
| Feb 5, 2026 | Buy | JNJ | Elizabeth Forminard | EVP, Chief Legal Officer | 15,147 | $174.06 | $609.1B | -6.08% | +55.91% | $2.6M | +7.78% | — | Stalk |
| Jan 26, 2026 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 100,000 | $221.23 | $609.1B | -6.08% | +55.91% | $22.1M | -47.51% | — | Stalk |
| Oct 17, 2025 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 43,442 | $175.31 | $609.1B | -6.08% | +55.91% | $7.6M | +0.00% | — | Stalk |
| Sep 4, 2025 | Sell | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 112,942 | $139.84 | $609.1B | -6.08% | +55.91% | $15.8M | +0.00% | — | Stalk |
| Aug 29, 2025 | Buy | JNJ | Elizabeth Forminard | Executive VP, General Counsel | 21,091 | $143.59 | $609.1B | -6.08% | +55.91% | $3.0M | +5.85% | — | Stalk |
| Aug 22, 2025 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 251,648 | $140.54 | $609.1B | -6.08% | +55.91% | $35.4M | +0.00% | — | Stalk |
| Aug 15, 2025 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 33,640 | $139.39 | $609.1B | -6.08% | +55.91% | $4.7M | +0.00% | — | Stalk |
| Jul 17, 2025 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 19,137 | $163.55 | $609.1B | -6.08% | +55.91% | $3.1M | -64.23% | — | Stalk |
| May 1, 2025 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 11,002 | $156.31 | $609.1B | -6.08% | +55.91% | $1.7M | -16.66% | — | Stalk |
| Mar 18, 2025 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 261,704 | $164.25 | $609.1B | -6.08% | +55.91% | $43.0M | +0.00% | — | Stalk |
| Feb 25, 2025 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 13,998 | $133.88 | $609.1B | -6.08% | +55.91% | $1.9M | +0.00% | — | Stalk |
| Feb 18, 2025 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 385 | $156.15 | $609.1B | -6.08% | +55.91% | $60.1K | -2.07% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 824 | $156.46 | $609.1B | -6.08% | +55.91% | $128.9K | -1.01% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Kristen Mulholland | EVP, Chief HR Officer | 1,008 | $156.44 | $609.1B | -6.08% | +55.91% | $157.7K | -1.87% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 1,015 | $156.71 | $609.1B | -6.08% | +55.91% | $159.1K | -5.67% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 1,235 | $156.30 | $609.1B | -6.08% | +55.91% | $193.0K | -2.64% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Elizabeth Forminard | Executive VP, General Counsel | 1,253 | $156.32 | $609.1B | -6.08% | +55.91% | $195.9K | -2.92% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | James D. Swanson | EVP, CIO | 1,740 | $156.54 | $609.1B | -6.08% | +55.91% | $272.4K | -2.49% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 1,880 | $156.55 | $609.1B | -6.08% | +55.91% | $294.3K | -2.09% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 3,296 | $156.58 | $609.1B | -6.08% | +55.91% | $516.1K | -0.89% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 9,080 | $156.58 | $609.1B | -6.08% | +55.91% | $1.4M | -22.95% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 10,320 | $156.62 | $609.1B | -6.08% | +55.91% | $1.6M | -1.48% | — | Stalk |
| Feb 14, 2025 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 13,696 | $156.48 | $609.1B | -6.08% | +55.91% | $2.1M | -0.85% | — | Stalk |
| Feb 7, 2025 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 26,030 | $126.97 | $609.1B | -6.08% | +55.91% | $3.3M | +0.00% | — | Stalk |
| Feb 7, 2025 | Buy | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 58,838 | $123.58 | $609.1B | -6.08% | +55.91% | $7.3M | +3.39% | — | Stalk |
| Feb 7, 2025 | Buy | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 105,940 | $123.82 | $609.1B | -6.08% | +55.91% | $13.1M | +3.01% | — | Stalk |
| Feb 7, 2025 | Buy | JNJ | Joaquin Duato | CEO and Chairman of the Board | 227,012 | $123.58 | $609.1B | -6.08% | +55.91% | $28.1M | +3.02% | — | Stalk |
| Aug 30, 2024 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 11,270 | $132.56 | $609.1B | -6.08% | +55.91% | $1.5M | +0.00% | — | Stalk |
| Jul 8, 2024 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 5,018 | $147.16 | $609.1B | -6.08% | +55.91% | $738.4K | -20.19% | — | Stalk |
| May 22, 2024 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 137,725 | $153.50 | $609.1B | -6.08% | +55.91% | $21.1M | -0.04% | — | Stalk |
| May 1, 2024 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 10,984 | $144.59 | $609.1B | -6.08% | +55.91% | $1.6M | -14.44% | — | Stalk |
| May 1, 2024 | Sell | JNJ | John C Reed | EVP, Innovative Medicine, R&D | 10,984 | $144.59 | $609.1B | -6.08% | +55.91% | $1.6M | -14.44% | — | Stalk |
| Mar 13, 2024 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 8,891 | $162.16 | $609.1B | -6.08% | +55.91% | $1.4M | -37.15% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 86 | $157.85 | $609.1B | -6.08% | +55.91% | $13.6K | -0.44% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | James D. Swanson | EVP, CIO | 195 | $157.85 | $609.1B | -6.08% | +55.91% | $30.8K | -1.25% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 209 | $157.85 | $609.1B | -6.08% | +55.91% | $33.0K | -0.84% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Elizabeth Forminard | Executive VP, General Counsel | 236 | $157.85 | $609.1B | -6.08% | +55.91% | $37.3K | -2.39% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 250 | $157.85 | $609.1B | -6.08% | +55.91% | $39.5K | -1.75% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 333 | $157.85 | $609.1B | -6.08% | +55.91% | $52.6K | -0.40% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | William Hait | — | 427 | $157.85 | $609.1B | -6.08% | +55.91% | $67.4K | -1.05% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Peter Fasolo | Exec VP, Chief HR Officer | 474 | $157.85 | $609.1B | -6.08% | +55.91% | $74.8K | -0.41% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 666 | $157.85 | $609.1B | -6.08% | +55.91% | $105.1K | -0.42% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 773 | $157.85 | $609.1B | -6.08% | +55.91% | $122.0K | -1.06% | — | Stalk |
| Feb 13, 2024 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 1,507 | $157.85 | $609.1B | -6.08% | +55.91% | $237.9K | -0.41% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 523 | $157.40 | $609.1B | -6.08% | +55.91% | $82.3K | -2.71% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Elizabeth Forminard | Executive VP, General Counsel | 1,034 | $157.40 | $609.1B | -6.08% | +55.91% | $162.8K | -11.54% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | James D. Swanson | EVP, CIO | 1,695 | $157.40 | $609.1B | -6.08% | +55.91% | $266.8K | -10.59% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 2,136 | $157.40 | $609.1B | -6.08% | +55.91% | $336.2K | -8.26% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 2,887 | $157.40 | $609.1B | -6.08% | +55.91% | $454.4K | -18.41% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | William Hait | — | 4,076 | $157.40 | $609.1B | -6.08% | +55.91% | $641.6K | -9.63% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Peter Fasolo | Exec VP, Chief HR Officer | 7,019 | $157.40 | $609.1B | -6.08% | +55.91% | $1.1M | -5.92% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 7,066 | $157.40 | $609.1B | -6.08% | +55.91% | $1.1M | -7.94% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 10,816 | $157.40 | $609.1B | -6.08% | +55.91% | $1.7M | -13.74% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Jennifer L Taubert | EVP, WWC. Innovative Medicine | 13,403 | $157.40 | $609.1B | -6.08% | +55.91% | $2.1M | -8.00% | — | Stalk |
| Feb 12, 2024 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 15,900 | $157.40 | $609.1B | -6.08% | +55.91% | $2.5M | -4.21% | — | Stalk |
| Feb 9, 2024 | Buy | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 62,971 | $119.23 | $609.1B | -6.08% | +55.91% | $7.5M | +4.90% | — | Stalk |
| Feb 9, 2024 | Buy | JNJ | Joaquin Duato | CEO and Chairman of the Board | 229,631 | $118.93 | $609.1B | -6.08% | +55.91% | $27.3M | +4.32% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Robert J Decker | VP Corporate Controller | 215 | $156.33 | $609.1B | -6.08% | +55.91% | $33.6K | -1.22% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Elizabeth Forminard | Executive VP, General Counsel | 363 | $156.33 | $609.1B | -6.08% | +55.91% | $56.7K | -5.62% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | James D. Swanson | — | 554 | $156.33 | $609.1B | -6.08% | +55.91% | $86.6K | -4.99% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Vanessa Broadhurst | EVP, Global Corp Affairs | 703 | $156.33 | $609.1B | -6.08% | +55.91% | $109.9K | -3.33% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Peter Fasolo | Exec VP, Chief HR Officer | 781 | $156.33 | $609.1B | -6.08% | +55.91% | $122.1K | -0.75% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Timothy Schmid | EVP, WW Chair, MedTech | 1,001 | $156.33 | $609.1B | -6.08% | +55.91% | $156.5K | -9.15% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Kathryn E Wengel | EVP, Chief TO and Risk Officer | 1,009 | $156.33 | $609.1B | -6.08% | +55.91% | $157.7K | -1.49% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Joseph J Wolk | Exec VP, CFO | 1,047 | $156.33 | $609.1B | -6.08% | +55.91% | $163.7K | -1.94% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | William Hait | — | 1,113 | $156.33 | $609.1B | -6.08% | +55.91% | $174.0K | -2.96% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Joaquin Duato | CEO and Chairman of the Board | 2,269 | $156.33 | $609.1B | -6.08% | +55.91% | $354.7K | -0.73% | — | Stalk |
| Feb 8, 2024 | Sell | JNJ | Jennifer L Taubert | EVP, WW Chair, Pharmaceuticals | 120,707 | $123.88 | $609.1B | -6.08% | +55.91% | $15.0M | -0.39% | — | Stalk |